Gefitinib induces myeloid differentiation of acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

http://www.wikidata.org/entity/Q42742416

about

A gene expression profile of stem cell pluripotentiality and differentiation is conserved across diverse solid and hematopoietic cancers Signal transduction inhibitors in treatment of myelodysplastic syndromes Discovering hidden connections among diseases, genes and drugs based on microarray expression profiles with negative-term filtering Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells Differentiation therapy of leukemia: 3 decades of development.Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.Proteomic and genetic approaches identify Syk as an AML target.SYK regulates mTOR signaling in AML.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.Genetic and proteomic approaches to identify cancer drug targets.New sources of drugs for hematologic malignancies Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.Erlotinib antagonizes ABC transporters in acute myeloid leukemia.Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia HOXA9 is required for survival in human MLL-rearranged acute leukemias.Genomic approaches to small molecule discovery.EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells Is there a role for differentiating therapy in non-APL AML?Systems biology visualization tools for drug target discovery.Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis.Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues.Identification of new possible targets for leukemia treatment by kinase activity profiling.Guanosine 5'-triphosphate induces differentiation-dependent apoptosis in human leukemia U937 and KG1 cells.Gefitinib potentiates myeloid cell differentiation by ATRA Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia.Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.

P2860

Q21999537-6630564B-8466-46F1-BF6F-8313E4DD0B9D Q26829903-10C7F733-7135-43D9-BA8D-1FAAE3FC516A Q28539530-F5816EED-1FA8-46A4-AF16-CAE9F6C40092 Q28548235-F76EA1C5-E600-4983-84B9-C0781FCCC26D Q33409795-3C204F09-D915-41D2-939E-D3DB30089460 Q33526746-C4A435A8-C28F-48D6-AACE-3B4DBFEF2892 Q33577098-E75FB388-87D9-496C-9FEA-EF7BF2E84460 Q33641643-52222400-34BE-46DD-9639-94C3B26C04F6 Q33775647-80F9ECDD-D75C-4C15-9469-F4A5B907941D Q34069315-14C00479-3A91-4668-A09C-794AE4EA6B2C Q34117127-71DE7B39-512D-4C4E-9414-2326769A40D9 Q34335004-9D33362D-AB03-4C20-809E-0811968FEC11 Q34794431-74CD18E0-8D76-43AB-BD89-5E3F3CE05545 Q35030829-D5152F09-6747-4AAE-A0F1-CA8E59F4EB79 Q35093305-93E920D8-8CAE-4EB4-BD86-680E1B852B2D Q35536200-4B6EEDA8-CA9D-4E9C-909A-439C322D12C0 Q35569079-491DF13F-7136-423B-A7E2-5F67774B29D3 Q35683353-E024947D-6FE7-4D5A-BB64-0ECA2C67C9B3 Q35979113-5E098CAB-DCB4-419B-A494-10786F02986A Q36291109-2DDB7833-5F67-4E32-AC1A-56DF1FA065E1 Q36426524-02293980-A954-427C-9A3E-3ADFB82ADA03 Q36882696-E05E3FBB-0BFF-4948-AE59-2F114B284EC6 Q37123272-579042A1-07B4-480A-A7F0-32B3BBF4AC9D Q37129652-EA411D89-3407-4FC2-8895-12D3FF6E379E Q37406963-2AC44AC6-919B-4996-9CED-E9EC11E04D64 Q37420045-E2FF8761-46B4-44EF-931D-A5E408CA68FD Q37815790-C102C311-51C6-4692-99B3-245DAA832677 Q38028544-E9E7883E-127B-4D83-A0EC-33BDD3A808A6 Q38719813-E33A1CB0-F0B5-4A65-BD5B-BEC6E4B366AF Q39013880-C0477250-E725-4CC4-897C-DE3A2C6BB208 Q39255686-FEE76FBE-2C77-46D2-99D4-0F8E00AF28BD Q39335663-5E0E3F64-A095-40F2-BE5F-259C40E0EFC5 Q39439229-79B7D935-3E7A-45A4-AC75-6FDDA08AC3CD Q39460944-EBFC4D37-C99A-4D8A-8ECA-D6BD17B0F7B3 Q39623499-D6A91C8C-9349-4EFF-8894-3A1450CA653F Q40241248-A87D5703-F918-42FB-9521-879FA99C9946 Q41181298-56BAAD06-A119-483C-A218-9D6599BBA93E Q42362038-5EFBD674-1AA7-4264-AB61-D5C2A0E26C9B Q42383776-DF3A4A65-5C7C-4DE7-BF7D-D078D0E1A38B Q42919966-DA894C99-3EE8-4CD7-A357-D5B7E2E4FD92

P2860

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

http://www.wikidata.org/entity/Q42742416

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@en

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@nl

type

label

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@en

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@nl

prefLabel

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@en

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@nl

P1433

Q42742416-48620984-36A3-4FC4-8FDD-E04CA211D9F5

P1476

Q42742416-24242744-6CFE-4733-AFEE-A8A20BD8B5E5

P2093

Q42742416-1035785C-822B-40C6-904C-BCF84DAA322F

Q42742416-257132AA-BE45-4C84-BD6C-24296AD495B5

Q42742416-5CD963A0-08EA-46ED-84D4-2BF1203D749C

Q42742416-603D731D-765B-4202-8177-5DCE2DD8FDEE

Q42742416-E73E5E37-7028-4934-94EA-381B5EEE0EEC

P2860

Q42742416-02AE71AF-244E-42DB-AECF-F6E3021A22DB

Q42742416-1DAAB9D4-8949-41B2-8755-8770F95F2433

Q42742416-2222F46C-9079-4BE9-8360-C57974F3E326

Q42742416-2CF9C4F1-AC6A-4AA9-A464-EAA9AEE020F0

Q42742416-335D0C6B-E136-48A8-BE93-8F3CEE9261BE

Q42742416-361F85AA-DD5A-4B01-ADFB-8601D691CE87

Q42742416-37C6FAB0-8731-4A39-AE64-FAD394547657

Q42742416-4A3E423B-784A-4300-AB9C-80E87ACD3399

Q42742416-4DEE9CF8-4C08-4EEA-9B4E-14BBB5F22D40

Q42742416-4E64DA21-6B51-4F79-BAB0-70565C9003C9

P304

Q42742416-E23F9B0B-F4A4-4E9A-BDD0-080B2979D252

P31

Q42742416-99935CFA-7EC8-4CFB-AE6E-497442E5C0A5

P356

Q42742416-B79F830B-5592-404B-A99C-11BB03CB47F6

P407

Q42742416-E06A67AD-598C-4403-9DD5-9483779508B8

P433

Q42742416-62862CAD-1F55-46A6-81BB-DE2A769834E0

P478

Q42742416-5E52FD91-BDDE-42CD-930E-DDA433B89AA2

P50

Q42742416-D1E62F38-613E-4EC3-BE6E-B24358A7BF9D

P577

Q42742416-1F4C04C4-EFAE-4807-B027-4D9A7E635D13

P5875

Q42742416-A629EA91-F8CD-4B80-A3D8-415D1E946339

P698

Q42742416-51FEE0BB-4094-4583-8C1F-1DDDFF2E966F

P921

Q42742416-388FA933-01E3-4BF1-8F46-D12D58DC7674

P932

Q42742416-E7B0B6D2-06EF-4A4A-B19F-19AD3A595CFF

P356

BLOOD-2005-02-0488

P1433

P1476

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

@en

P2093

Daniel J Deangelo

http://www.w3.org/2001/XMLSchema#string

Jenny S Wong

http://www.w3.org/2001/XMLSchema#string

Kenneth N Ross

http://www.w3.org/2001/XMLSchema#string

Steven M Corsello

http://www.w3.org/2001/XMLSchema#string

Todd R Golub

http://www.w3.org/2001/XMLSchema#string

P2860

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group

The detection of disease clustering and a generalized regression approach

A small molecule-kinase interaction map for clinical kinase inhibitors

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.

Differentiation therapy in acute myelogenous leukemia (non-APL).

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

RETRACTED: 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

P304

2841-2848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-02-0488

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly Stegmaier

P577

2005-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7745131

http://www.w3.org/2001/XMLSchema#string

P698

15998836

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895296

http://www.w3.org/2001/XMLSchema#string